Cooley advised Sucampo Pharmaceuticals on its acquisition of rare disease biotech firm Vtesse for $200 million in cash and stock in upfront payments and contingent payments based on net sales of the acquired product.
The purchase provides Sucampo access to VTS-270, a product candidate undergoing study for the treatment of Niemann-Pick Disease Type C1 (NPC).
Vtesse and Sucampo intend to establish a foundation to support research related to NPC. Subject to finalizing the terms of the foundation, Vtesse’s equity holders have set aside a portion of the transaction proceeds to contribute to the foundation. Sucampo intends to match the Vtesse shareholder contribution from its corporate funds.
Sucampo, which trades on The NASDAQ Global Market as “SCMP,” is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. In 2015, Cooley advised Sucampo on its acquisition of R-Tech Ueno.
Cooley has advised with a team including Barbara Borden (Picture), Christian Plaza, Marc Samuel, Eric Dixon, Micah Youngdale, Edmond Lay, Mike Faber, Stephanie Gentile, Amanda Pacheco, David Walsh, Mary Lewis, Brent Siler, Brian Leaf, Madison Jones, Natasha Leskovsek, Thomas Paxton, Kenneth Krisko, Stephanie Parker Palmer, Kristy Brady, John Hoover, Jacqueline Grise, Parker Erkmann and Sharon Connaughton.
Involved fees earner: Barbara Borden – Cooley LLP; Christian Plaza – Cooley LLP; Marc Samuel – Cooley LLP; Eric Dixon – Cooley LLP; Micah Youngdale – Cooley LLP; Edmond Lay – Cooley LLP; Mike Faber – Cooley LLP; Stephanie Gentile – Cooley LLP; Amanda Pacheco – Cooley LLP; John Hoover – Cooley LLP; David Walsh – Cooley LLP; Mary Lewis – Cooley LLP; Brent Siler – Cooley LLP; Brian Leaf – Cooley LLP; Madison Jones – Cooley LLP; Natasha Leskovsek – Cooley LLP; Kenneth Krisko – Cooley LLP; Stephanie Parker Palmer – Cooley LLP; Kristy Brady – Cooley LLP; Thomas Paxton – Cooley LLP; Jacqueline Grise – Cooley LLP; Parker Erkmann – Cooley LLP; Sharon Connaughton – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Sucampo Pharmaceuticals, Inc.;